Pralatrexate
- Introduction
- Newest Products
Introduction
Pralatrexate
Pralatrexate, an injectable DHFR inhibitor, was launched for the treatment of patients with relapsed or refractory PTCL. The inhibition of the folate enzymes DHFR and thymidylate synthase is a well-validated method of cancer treatment.
Newest Products
| Image | Part # | Description | manufacturer | Stock | RFQ | |
|---|---|---|---|---|---|---|
|
|
6-(Bromomethyl)-2,4-pteridinediamine hydrobromide (52853-40-4) |
CAS: 52853-40-4; anti-tumor ; pralatrexate t cell lymphoma; intermediate
|
|
In Stock
|
|
|
|
|
Pralatrexate (146464-95-1) |
CAS: 52853-40-4; anti-tumor ; pralatrexate t cell lymphoma
|
|
In Stock
|
|
